SCHEMBL4246332

SCHEMBL4246332

CCn1ccc(C(=O)O)cc1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.47
HCAR3 P49019 1/20 0.41
KDM5A P29375 2/20 0.40
KDM4C Q9H3R0 2/20 0.40
KDM5B Q9UGL1 2/20 0.40
ACACB O00763 1/20 0.39
ALDH1A1 P00352 4/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
PIK3CD O00329 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
PI4KA P42356 1/20 0.38
PIK3CG P48736 1/20 0.38
PI4KB Q9UBF8 1/20 0.38
KDM4E B2RXH2 3/20 0.37
ALOX15 P16050 1/20 0.37
HPGD P15428 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13522478 0.86 POLB (0.44) POLBHCAR3KDM5AKDM4CKDM5B
SCHEMBL12734354 0.85 ACACB (0.42) POLBACACBKMT2AMEN1NPC1
SCHEMBL841380 0.83 HCAR3 (0.46) POLBHCAR3KDM5AKDM4CKDM5B
SCHEMBL6166241 0.83 POLB (0.40) POLBHCAR3KDM5AKDM4CKDM5B
SCHEMBL13522483 0.82 KDM4E (0.47) HCAR3KDM5AKDM4CKDM5BALDH1A1
SCHEMBL13702358 0.81 PLK1 (0.43) ACACBKMT2AMEN1PIK3CDPIK3CA
SCHEMBL13522480 0.81 MEN1 (0.36) POLBKDM5AKDM4CKDM5BALDH1A1
SCHEMBL1014690 0.81 B3GNT2 (0.47) POLBKDM5AKDM4CKDM5BACACB
SCHEMBL13876015 0.81 ACACB (0.37) POLBACACBPIK3CDPIK3CAPIK3CB
SCHEMBL13702294 0.80 PIK3CA (0.43) ACACBALDH1A1KMT2AMEN1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025124429-A1 AROMATIC AMINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京康辰药业股份有限公司 2025-06-19 WO disclosed
WO-2010000401-A1 USE OF SUBSTITUTED PYRIDINONE CARBOXYLIC ACID DERIVATES FOR PRODUCING PHARMACEUTICALS FOR THE TREATMENT OF DYSLIPIDEMIA SANOFI-AVENTIS (FR) 2010-01-07 WO disclosed
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors FLECK ROMAN WOLFGANG 2009-09-10 US disclosed
CN-100528864-C N-substituted-2-oxodihydropyridine derivative BANYU PHARMA CO LTD (JP) 2009-08-19 CN disclosed
EP-1960367-A2 SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2008-08-27 EP disclosed
WO-2007067836-A2 SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-14 WO disclosed
CN-1684954-A N-substituted-2-oxodihydropyridine derivative BANYU PHARMA CO LTD (JP) 2005-10-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors EPHX1, EPHX2, EPX POLB 1495/4885HCAR3 429/4885KDM5A 1576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.